Perth-based burns treatment developer Clinical Cell Culture Ltd, or C3, will raise $10 million through a share purchase plan to existing shareholders for further commercialisation of the company's ReCell product.
25/10/2006 - 09:51
C3 to raise $10m through underwritten share purchase plan
25/10/2006 - 09:51
